Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2013

View Archived Issues

NCI awards fast-track grant to G1 Therapeutics for GZ38-1

Improvement demonstrated in patients with IBS-D treated with EnteraGam

Radiolabeled PET tracer shows selectivity and good brain penetration for in vivo imaging

Phase I/II trial investigates UC-1010 for premenstrual dysphoric disorder

Gene replacement therapy demonstrates good safety in patients with Pompe's disease

In vivo and in vitro antibacterial activity of RPX-978

Identification of a DMOAD candidate for osteoarthritis treatment

New genetic test for patients with cirrhosis at high risk for liver cancer

AbbVie presents new TRPV3 antagonists

Researchers at Merck & Co. present novel CETP inhibitors

New protein kinase B inhibitors patented by Taiho Pharmaceuticals

Japanese researchers patent novel ACC inhibitors

U.S. and Japanese scientists synthesize new coagulation factor IXa inhibitors

Circassia begins proof-of-principle study for PAP-1 in psoriasis

miRagen Therapeutics achieves milestone in alliance with Servier

Takeda begins phase III trial of MLN-9708 in newly diagnosed multiple myeloma

University of Tromso and Biosortia Pharmaceuticals enter collaboration

OncoGenex plans Cedar(TM) trial initiation

Taisho Pharmaceutical discloses new mGlu2 receptor positive allosteric modulators

FDA clears IND for OMS-824 in Huntington's disease

Zensun reports on global phase II program for Neucardin

Chugai launches Actemra subcutaneous injection in Japan

FDA grants priority review to Abraxane sNDA in advanced pancreatic cancer

Lpath begins dosing in first proof-of-concept trial of ASONEP

AbbVie and Eisai gain new indication approval for Humira Pre-filled Syringe in Japan

GlaxoSmithKline launches Arzerra in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.